Glitazones in the treatment of diabetes mellitus: clinical outcomes in large scale clinical trials.
Only one large scale cardiovascular outcome study has been completed and published for the thiazolidines-iones in type 2 diabetes, the PROactive study which demonstrates a strong trend in favour of a specific cardioprotective effect of pioglitazone. The other available data, published as meta-analyses, suggest that there is a difference in this regard between pioglitazone and rosiglitazone.
Charbonnel
Bernard
B
Department of Endocrinology and Diabetes, University Hospital, Nantes, France. bernard.charbonnel@univ-nantes.fr
D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000077205:Pioglitazone; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*; D016896:Treatment Outcome
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone